#USA #New York #Levi & Korsinsky #MoonLake #MLTX

Class Action Lawsuit Filed Against MoonLake Immunotherapeutics

Overview
MoonLake Immunotherapeutics, a company listed on NASDAQ under the ticker MLTX, is facing a class action lawsuit initiated by Levi & Korsinsky, LLP. The lawsuit centers around allegations of securities fraud that affected investors during a specific time frame. If you are an investor in MoonLake, it’s crucial to understand your rights and options moving forward.

Details of the Lawsuit
The class action seeks to recover losses for shareholders who experienced financial detriment as a result of alleged fraudulent activities by the defendants. The class period outlined in the case spans from March 10, 2024, to September 29, 2025. According to the complaint, the defendants purportedly made misleading statements regarding the company’s drug candidate, SLK, and its presumed superiority over BIMZELX, a comparable medication.

The allegations include claims that:
1. Both SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F).
2. The distinct structure of SLK, referred to as a Nanobody, may not offer clinical benefits that exceed those provided by BIMZELX, which uses traditional monoclonal technology.
3. Assertions regarding SLK's increased ability to penetrate tissues do not directly translate to improved clinical outcomes for patients.
4. Hence, the defendants lacked a reasonable basis for making positive claims about SLK’s efficacy compared to monoclonal antibodies.

What Should Investors Do?
Investors who believe they have been impacted by the alleged securities fraud should act quickly. The window to request to be appointed as a lead plaintiff in this class action lawsuit is open until December 15, 2025. Filing as a lead plaintiff is not a requirement to obtain compensation, but it can provide you a more significant role in the litigation process.

If you are interested in learning more about your potential eligibility and the process involved, you can reach out to the legal team at Levi & Korsinsky for guidance. Those impacted can fill out their submission form available on their website, which facilitates swift communication with their legal team.

No Financial Burden
For investors who are part of the class, it’s crucial to know that participating in this lawsuit will involve no upfront costs or obligations. Compensation can be sought without the necessity for any out-of-pocket payments. Given the reputation of Levi & Korsinsky, known for securing substantial settlements for their clients, investors may feel more confident in pursuing legal action.

About Levi & Korsinsky
Levi & Korsinsky, LLP has a longstanding history of representing investors in complex securities litigation. For over two decades, the firm has established itself as a reputable player in the legal field, known for its success in handling high-stakes cases. Furthermore, the firm consistently features in top listings for securities litigation firms in the United States, including the ISS Securities Class Action Services' Top 50 Report.

Conclusion

Investors in MoonLake Immunotherapeutics should stay informed about their rights in the wake of this class action lawsuit. Filing as a lead plaintiff or participating in the lawsuit can help recover losses incurred from potential fraudulent activities. Remember, the deadline to act is December 15, 2025, so it's essential to reach out to Levi & Korsinsky if you have been negatively affected by this situation.